Skip to search formSkip to main contentSkip to account menu

lonafarnib/paclitaxel/trastuzumab

Known as: MOAB HER2/SCH 66336/TAX 
National Institutes of Health

Related topics

Related topics

3 relations
Paclitaxellonafarnibtrastuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Farnesyl transferase (FT) inhibitors (FTI) are anticancer agents developed to target oncogenic Ras proteins by inhibiting Ras… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)